- /
- Supported exchanges
- / US
- / RHHVF.OTCQX
Roche Holding AG Participation (RHHVF OTCQX) stock market data APIs
Roche Holding AG Participation Financial Data Overview
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Roche Holding AG Participation (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Roche Holding AG Participation data using free add-ons & libraries
Get Roche Holding AG Participation Fundamental Data
Roche Holding AG Participation Fundamental data includes:
- Net Revenue: 63 488 M
- EBITDA: 23 429 M
- Earnings Per Share: 14
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-23
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roche Holding AG Participation News
New
Looking at the Narrative for Roche After New Trial Results and Strategic Shifts
Roche Holding’s fair value estimate has edged up to about CHF 312 from roughly CHF 305, supported by a slightly higher long term revenue growth outlook of around 1.51% versus about 1.48% previously....
3 Global Stocks Estimated To Be Trading At Discounts Of 34.7% To 47.8%
As global markets navigate a landscape marked by dovish Federal Reserve comments, subdued inflation in the eurozone, and resilient economic indicators in Japan, investors are increasingly focused on i...
Bio/Pharmaceutical Outsourcing Report, October 2025 - Pfizer and Roche Place $10 Billion Bets on Obesity and Liver Disease Therapies as Trump Tightens Grip on Drug Pricing and Manufacturing
Company Logo The report highlights opportunities in pharmaceutical outsourcing through emerging trends, new contracts, M&A activities, and investments in technology. It guides CMOs, pharmaceutical de...
Orano Med Enters Next Phase of Collaboration with Roche
PARIS, December 04, 2025--(BUSINESS WIRE)--Regulatory News: Orano Med, a subsidiary of the Orano group specializing in nuclear medicine, announced today that its long-standing collaboration with the ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.